ProCE Banner Activity

KEYNOTE-671: Pembrolizumab or Placebo + Platinum-Based Neoadjuvant Chemotherapy Followed by Resection and Adjuvant Pembrolizumab or Placebo in Early-Stage NSCLC

Conference Coverage
Slideset

In patients with resectable stage II, IIIA, or IIIB (N2) NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab was associated with a significant improvement in EFS vs neoadjuvant chemotherapy and surgery alone.

Released: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure